{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:02:32Z","timestamp":1768712552505,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1124\/jpet.122.001230","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T15:15:24Z","timestamp":1659712524000},"page":"91-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors"],"prefix":"10.1016","volume":"383","author":[{"given":"Surabhi","family":"Talele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiv K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle M.","family":"Burgenske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jann N.","family":"Sarkaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William F.","family":"Elmquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001230_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.122.001230_bib2","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2174\/138161211797440186","article-title":"Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up","volume":"17","author":"Agarwal","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1124\/jpet.122.001230_bib3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/jpet.110.167601","article-title":"Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux","volume":"334","author":"Agarwal","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001230_bib4","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1017\/S1462399411001888","article-title":"Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain","volume":"13","author":"Agarwal","year":"2011","journal-title":"Expert Rev Mol Med"},{"key":"10.1124\/jpet.122.001230_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01062139","article-title":"Testing for the equality of area under the curves when using destructive measurement techniques","volume":"16","author":"Bailer","year":"1988","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/jpet.122.001230_bib6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neuropharm.2006.07.038","article-title":"Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein","volume":"52","author":"Baltes","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.122.001230_bib7","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-12-3408","article-title":"ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation","volume":"19","author":"Biddlestone-Thorpe","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.122.001230_bib8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molonc.2014.08.003","article-title":"Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase","volume":"9","author":"Carruthers","year":"2015","journal-title":"Mol Oncol"},{"issue":"Suppl 16","key":"10.1124\/jpet.122.001230_bib9","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1158\/1538-7445.AM2020-6506","article-title":"Abstract 6506: targeting ATM with AZD1390 for radio-sensitization of glioblastoma patient derived xenografts","volume":"80","author":"Chen","year":"2020","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.122.001230_bib10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/17425255.2013.741589","article-title":"Species differences in drug transporters and implications for translating preclinical findings to humans","volume":"9","author":"Chu","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/jpet.122.001230_bib11","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.ijrobp.2021.08.003","article-title":"Preclinical risk evaluation of normal tissue injury with novel radiosensitizers","volume":"111","author":"Dragojevic","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 1","key":"10.1124\/jpet.122.001230_bib12","doi-asserted-by":"crossref","first-page":"A104","DOI":"10.1158\/1535-7163.TARG-17-A104","article-title":"Abstract A104: AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models (Abstract)","volume":"17","author":"Durant","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.122.001230_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aat1719","article-title":"The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models","volume":"4","author":"Durant","year":"2018","journal-title":"Sci Adv"},{"key":"10.1124\/jpet.122.001230_bib14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/dmd.107.017434","article-title":"In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system","volume":"36","author":"Feng","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001230_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.110.035998","article-title":"Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods","volume":"39","author":"Frid\u00e9n","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001230_bib16","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1038\/s41598-020-63494-7","article-title":"Enhancing brain retention of a KIF11 inhibitor significantly improves its efficacy in a mouse model of glioblastoma","volume":"10","author":"Gampa","year":"2020","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.122.001230_bib17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1080\/02841860152619115","article-title":"The inherited basis of human radiosensitivity","volume":"40","author":"Gatti","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1124\/jpet.122.001230_bib18","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.4161\/cc.11.6.19576","article-title":"Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control","volume":"11","author":"Golding","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1124\/jpet.122.001230_bib19","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.21873\/anticanres.15347","article-title":"Large animal models of glioma: current status and future prospects","volume":"41","author":"Hicks","year":"2021","journal-title":"Anticancer Res"},{"key":"10.1124\/jpet.122.001230_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejps.2018.06.022","article-title":"Interspecies comparison of putative ligand binding sites of human, rat and mouse P-glycoprotein","volume":"122","author":"Jain","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/jpet.122.001230_bib21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/noaa238","article-title":"Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study","volume":"23","author":"Jucaite","year":"2021","journal-title":"Neuro-oncol"},{"key":"10.1124\/jpet.122.001230_bib22","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1158\/1535-7163.MCT-17-0975","article-title":"Orally bioavailable and blood-brain barrier-penetrating ATM inhibitor (AZ32) radiosensitizes intracranial gliomas in mice","volume":"17","author":"Karlin","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.122.001230_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/35043058","article-title":"The many substrates and functions of ATM","volume":"1","author":"Kastan","year":"2000","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1124\/jpet.122.001230_bib24","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/jps.20686","article-title":"Kinetic analyses for species differences in P-glycoprotein-mediated drug transport","volume":"95","author":"Katoh","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.122.001230_bib25","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1124\/jpet.109.162321","article-title":"Kinetic analysis of the cooperation of P-glycoprotein (P-gp\/Abcb1) and breast cancer resistance protein (Bcrp\/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone","volume":"333","author":"Kodaira","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001230_bib26","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41580-021-00394-2","article-title":"Cellular functions of the protein kinase ATM and their relevance to human disease","volume":"22","author":"Lee","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1124\/jpet.122.001230_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200342010-00003","article-title":"Role of P-glycoprotein in pharmacokinetics: clinical implications","volume":"42","author":"Lin","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.122.001230_bib28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","article-title":"Blood-brain barrier active efflux transporters: ATP-binding cassette gene family","volume":"2","author":"L\u00f6scher","year":"2005","journal-title":"NeuroRx"},{"key":"10.1124\/jpet.122.001230_bib29","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/cncr.32714","article-title":"Current multidisciplinary management of brain metastases","volume":"126","author":"Moravan","year":"2020","journal-title":"Cancer"},{"key":"10.1124\/jpet.122.001230_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10637-008-9138-z","article-title":"The effect of P-gp (Mdr1a\/1b), BCRP (Bcrp1) and P-gp\/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib","volume":"27","author":"Oostendorp","year":"2009","journal-title":"Invest New Drugs"},{"key":"10.1124\/jpet.122.001230_bib31","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/cpt.71","article-title":"Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier","volume":"97","author":"Parrish","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.122.001230_bib32","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.ijrobp.2009.02.057","article-title":"Clinical radiation sensitivity with DNA repair disorders: an overview","volume":"74","author":"Pollard","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1124\/jpet.122.001230_bib33","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/1097-0142(19820901)50:5<877::AID-CNCR2820500513>3.0.CO;2-U","article-title":"The effects of radiation therapy for Hodgkin\u2019s disease in a child with ataxia telangiectasia: a clinical, biological and pathologic study","volume":"50","author":"Pritchard","year":"1982","journal-title":"Cancer"},{"key":"10.1124\/jpet.122.001230_bib34","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1124\/dmd.112.045930","article-title":"Brain distribution and bioavailability of elacridar after different routes of administration in the mouse","volume":"40","author":"Sane","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001230_bib35","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro-oncol"},{"key":"10.1124\/jpet.122.001230_bib36","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0031-6997(25)07055-3","article-title":"Passage of drugs across body membranes","volume":"14","author":"Schanker","year":"1962","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.122.001230_bib37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1124\/dmd.121.000695","article-title":"Cynomolgus monkey as an emerging animal model to study drug transporters: in vitro, in vivo, in vitro-to-in vivo translation","volume":"50","author":"Shen","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001230_bib38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1124\/dmd.108.024745","article-title":"Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport","volume":"37","author":"Syv\u00e4nen","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001230_bib39","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1007\/s11095-006-0285-7","article-title":"Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1","volume":"23","author":"Takeuchi","year":"2006","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.122.001230_bib40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/jpet.121.000845","article-title":"Brain distribution of berzosertib: an ATR inhibitor for the treatment of glioblastoma","volume":"379","author":"Talele","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001230_bib41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1124\/jpet.121.001069","article-title":"CNS delivery of the DNA-PKcs inhibitor peposertib as radiosensitizer for brain metastases","volume":"381","author":"Talele","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001230_bib42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/088800102753541314","article-title":"Chemo- and radiosensitivity testing in a patient with ataxia telangiectasia and Hodgkin disease","volume":"19","author":"Tamminga","year":"2002","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1124\/jpet.122.001230_bib43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3322\/caac.21613","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 13","key":"10.1124\/jpet.122.001230_bib44","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1538-7445.AM2021-1388","article-title":"Abstract 1388: ATM inhibitor AZD1390 sensitizes breast cancer brain metastasis to radiation therapy (Abstract)","volume":"81","author":"Tew","year":"2021","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.122.001230_bib45","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1471-4159.2011.07208.x","article-title":"Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors","volume":"117","author":"Uchida","year":"2011","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.122.001230_bib46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.122.001230_bib47","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1124\/dmd.118.081216","article-title":"Characterization of P-glycoprotein humanized mice generated by chromosome engineering technology: its utility for prediction of drug distribution to the brain in humans","volume":"46","author":"Yamasaki","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001230_bib48","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0022-3565(24)38809-3","article-title":"In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results","volume":"296","author":"Yamazaki","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001230_bib49","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/jps.2600820718","article-title":"Estimation of variance for AUC in animal studies","volume":"82","author":"Yuan","year":"1993","journal-title":"J Pharm Sci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524003379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524003379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:26:59Z","timestamp":1739971619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524003379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0022356524003379"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001230","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}